Literature DB >> 1531117

Pharmacokinetics of sufentanil in normal children.

J Guay1, P Gaudreault, A Tang, B Goulet, F Varin.   

Abstract

The pharmacokinetic variables of sufentanil were studied in 20 healthy children between two and eight years of age. The plasma concentrations of sufentanil were measured for up to 480 min after administration of a bolus of sufentanil, 1-3 micrograms.kg-1. The distribution half-life (t1/2 alpha) was 5.2 +/- 2.2 (mean +/- SD) min and the elimination half life (t1/2 beta) was 97.0 +/- 42.0 min. The volume of distribution at steady state (Vdss) was 2.9 +/- 0.6 L.kg-1 and the clearance was 30.5 +/- 8.8 ml.kg-1.min-1. The Vdss was one and a half times greater than that reported in adults when expressed as a function of body weight but similar to that of adults when expressed as a function of body surface area. According to our results, the clearance of sufentanil in normal children between two and eight years of age is twice as rapid as that described in adults and adolescents. A greater clearance of sufentanil in children suggests that they would require relatively greater maintenance doses than adults.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531117     DOI: 10.1007/BF03008666

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  23 in total

Review 1.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

2.  Interaction of ketamine and halothane in rats.

Authors:  P F White; R R Johnston; C R Pudwill
Journal:  Anesthesiology       Date:  1975-02       Impact factor: 7.892

3.  Relationship of theophylline clearance to oral dosage in children with chronic asthma.

Authors:  E Ginchansky; M Weinberger
Journal:  J Pediatr       Date:  1977-10       Impact factor: 4.406

4.  Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure.

Authors:  P J Davis; R L Stiller; D R Cook; B W Brandom; K A Davin-Robinson
Journal:  Anesth Analg       Date:  1988-03       Impact factor: 5.108

5.  Acute diphenylhydantoin intoxication following halothane anesthesia.

Authors:  J M Karlin; H Kutt
Journal:  J Pediatr       Date:  1970-06       Impact factor: 4.406

6.  Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man.

Authors:  R E Stenson; R T Constantino; D C Harrison
Journal:  Circulation       Date:  1971-02       Impact factor: 29.690

7.  Changes in sufentanil pharmacokinetics within the neonatal period.

Authors:  W J Greeley; N P de Bruijn
Journal:  Anesth Analg       Date:  1988-01       Impact factor: 5.108

8.  The pharmacokinetics of sufentanil in surgical patients.

Authors:  J G Bovill; P S Sebel; C L Blackburn; V Oei-Lim; J J Heykants
Journal:  Anesthesiology       Date:  1984-11       Impact factor: 7.892

9.  Fentanyl- and sufentanil-oxygen-pancuronium anesthesia for cardiac surgery in infants.

Authors:  P R Hickey; D D Hansen
Journal:  Anesth Analg       Date:  1984-02       Impact factor: 5.108

10.  Hemodynamic and anesthetic effects of sufentanil as the sole anesthetic for pediatric cardiovascular surgery.

Authors:  R A Moore; S S Yang; K W McNicholas; J D Gallagher; D L Clark
Journal:  Anesthesiology       Date:  1985-06       Impact factor: 7.892

View more
  10 in total

1.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 3.  Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

5.  Pharmacokinetics of piritramide in newborns, infants and young children in intensive care units.

Authors:  Carsten Müller; Wolf Kremer; Steffi Harlfinger; Oxana Doroshyenko; Alexander Jetter; Fritz Hering; Christoph Hünseler; Bernhard Roth; Martin Theisohn
Journal:  Eur J Pediatr       Date:  2006-01-28       Impact factor: 3.183

6.  Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients.

Authors:  J Scholz; H Bause; M Schulz; U Klotz; D R Krishna; S Pohl; J Schulte am Esch
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

7.  Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure.

Authors:  In-Kyung Song; Ji-Hyun Lee; SungAe Jung; Jin-Tae Kim; Hee-Soo Kim
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

Review 8.  Attention to postoperative pain control in children.

Authors:  Ji Yeon Lee; Youn Yi Jo
Journal:  Korean J Anesthesiol       Date:  2014-03-28

9.  Effective Bolus Dose of Sufentanil to Attenuate Cardiovascular Responses in Laryngoscopic Double-Lumen Endobronchial Intubation.

Authors:  Byung-Hee Choi; Yong-Cheol Lee
Journal:  Anesth Pain Med       Date:  2016-04-04

10.  Comparison of the effect of different infusion rates of sufentanil on surgical stress index during cranial pinning in children under general anaesthesia: a randomized controlled study.

Authors:  In-Kyung Song; Sang-Hwan Ji; Eun-Hee Kim; Ji-Hyun Lee; Jin-Tae Kim; Hee-Soo Kim
Journal:  BMC Anesthesiol       Date:  2017-12-08       Impact factor: 2.217

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.